Verification register Bio, Health & Neuro
Current reading
Readiness band and full integer triple
AI-assisted assembly · derived results
Readiness band
Emerging
Primary summary from verified readiness
- Confidence
- 52% · stale
- Computed at
- 2026-08-20T10:56:25.283939+00:00
- Claimed
- 60
- Reported
- 41
- Verified
- 28
- Gap
- +32
Public ambition and stated capability
Observed practitioner reporting
Independently supported evidence
Claimed leads verified
Evidence strength Growing
Decision
What the current evidence supports
Human editorial judgment · 2026-08-20
Proceed with caution
- Why
- Approved and commercially marketed since 2023, but the required confirmatory trial missed its primary endpoint, three deaths from acute liver failure forced an FDA clinical hold and platform-designation revocation, Sarepta cut ~36% of its workforce, and the EU formally refused authorization for lack of demonstrated efficacy — the reference case now cuts both ways, as an approval template and as an accelerated-approval risk case study.
- Next
- Do not cite Elevidys as a de-risked precedent; track FDA's post-clinical-hold safety monitoring, real-world liver-toxicity data, and any confirmatory-trial resubmission before modeling new AAV micro-dystrophin or AAVrh74-platform programs on it.
Constraints
Blockers
No named blocker is present in the current public projection.
Evidence summary
Derived counts
AI-assisted assembly
- Total
- 6
- Tier 1
- 0
- Tier 2
- 4
- Tier 3
- 2
- Supports
- 1
- Contradicts
- 4
- Context
- 1
- Latest observed
- 2025-09-24
Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.
Publication record
Revisions
Initial public reading
- 2026-08-20 Reading moved from emerging to emerging.